Papiloma virus-like particles, fusion proteins as well as processes for their production

Details for Australian Patent Application No. 2003235191 (hide)

International Classifications

Event Publications

4 September 2003 Complete Application Filed

18 September 2003 Application Open to Public Inspection

Published as AU-B-2003235191

21 September 2006 Application Accepted

Published as AU-B-2003235191

18 January 2007 Standard Patent Sealed

29 November 2007 Amendment Made

The nature of the amendment is: Amend the invention title to read Papilloma virus-like particles, fusion proteins as well as processes for their production

14 February 2008 Extension of Term of Standard Patents

Loyola University of Chicago The earliest first regulatory approval date provided by the patentee 18 May 2007 For the goods Recombinant AS04 adjuvanted Cervarix Address for service in Australia: Shelston IP Level 21 60 Margaret Street Sydney NSW 2000

8 January 2009 Extension granted

Loyola University of Chicago The earliest first regulatory approval date provided by the patentee 18 May 2007 For the goods CERVARIX Human Papillomavirus Types 16 and 18 Extension of Term of patent pursuant to Section 77 expires on 09 Oct 2020

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.